Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

Hyperemia Clinical Trial

Official title:
A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in Healthy, Adult Subjects.

Status Completed

Clinical Trial Summary

To characterize the plasma pharmacokinetics and safety profile of brimonidine following a single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution 0.025% for 7 days in healthy, adult subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hyperemia

Clinical Trial Details

NCT number	NCT02039765
Study type	Interventional
Source	Bausch & Lomb Incorporated
Contact
Status	Completed
Phase	Phase 1
Start date	February 2014
Completion date	April 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02136589` - Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes	Phase 4
Completed	`NCT01959230` - Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness	Phase 3
Recruiting	`NCT05706181` - Heat Therapy, Functional Capacity, and Vascular Health in Older Adults	Phase 1/Phase 2
Completed	`NCT01642147` - Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy	N/A
Withdrawn	`NCT04132648` - Curcumin and Exercise in Chronic Kidney Disease	Phase 2
Recruiting	`NCT02183779` - PORH and Response to Cold in Raynaud's Phenomenon.	N/A
Completed	`NCT01959243` - Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants	Phase 3
Completed	`NCT00268554` - Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole	N/A